Capital on Demand Sales Agreement Sample Contracts
Serina Therapeutics, Inc. Common Stock ($0.0001 par value per share)Capital on Demand Sales Agreement • April 29th, 2025 • Serina Therapeutics, Inc. • Pharmaceutical preparations • New York
Serina Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
MEI PHARMA, INC. Common Stock ($0.00000002 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • February 21st, 2024 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
GREYSTONE HOUSING IMPACT INVESTORS LP Beneficial Unit Certificates Representing Assigned Limited Partnership Interests Amended and Restated Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • March 8th, 2024 • Greystone Housing Impact Investors LP • Finance services • New York
Reference is made to the Capital on DemandTM Sales Agreement, dated as of July 21, 2021 (the “Original Agreement”), by and between GREYSTONE HOLDING IMPACT INVESTORS LP (formerly known as America First Multifamily Investors, L.P.), a Delaware limited partnership (the “Partnership”), and JONESTRADING INSTITUTIONAL SERVICES LLC (“JonesTrading”), pursuant to which the Partnership proposed to issue and sell through JonesTrading, from time to time during the term of the Original Agreement, on the terms and subject to the conditions set forth in the Original Agreement, beneficial unit certificates representing assigned limited partnership interests of the Partnership (“BUCs”). The Partnership, JonesTrading, and BTIG, LLC (“BTIG”; each of JonesTrading and BTIG an “Agent” and collectively, the “Agents”) wish to amend and restate the Original Agreement in its entirety as provided hereby.
AEGLEA BIOTHERAPEUTICS, INC. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • May 20th, 2022 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through or to JonesTrading Institutional Services LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
INFINITY PHARMACEUTICALS, INC. Amendment No. 1 to Amended and Restated Capital on DemandTM Sales Agreement Sales AgreementCapital on Demand Sales Agreement • July 27th, 2021 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO CAPITAL ON DEMANDTM SALES AGREEMENTCapital on Demand Sales Agreement • March 16th, 2022 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”), together with JonesTrading Institutional Services LLC (the “Agent”), are parties to that certain Capital on DemandTM Sales Agreement dated December 9, 2020 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The Company and the Agent desire to amend the Original Agreement as set forth in this Amendment No. 1 thereto (this “Amendment”) as follows:
CNS Pharmaceuticals, Inc.Capital on Demand Sales Agreement • February 12th, 2021
We have entered into a Capital on Demand™ Sales Agreement, or sales agreement, with JonesTrading Institutional Services LLC, or JonesTrading, and Brookline Capital Markets, a division of Arcadia Securities, LLC, or Brookline, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $20.0 million from time to time through or to JonesTrading and Brookline (together, the “Agents”) acting as sales agent or principal, at our discretion.
VolitionRx Limited Common Stock (par value $0.001 per share) Amendment No. 1 to Capital on Demand™ Sales Agreement August 14, 2025Capital on Demand Sales Agreement • August 15th, 2025 • Volitionrx LTD • In vitro & in vivo diagnostic substances
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • November 14th, 2025 • RenovoRx, Inc. • Pharmaceutical preparations • New York
RenovoRx, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Common StockCapital on Demand Sales Agreement • January 13th, 2020
This prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement and the accompanying prospectus, dated January 13, 2020, are part of a registration statement on Form S-3 (File No. 333-235791) that we filed with the Securities and Exchange Commission (the “SEC”), utilizing a “shelf” registration process. Under the shelf registration process, we may offer and sell from time to time in one or more offerings our Common Stock described in the accompanying prospectus.
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 29th, 2025 • Unusual Machines, Inc. • Radio & tv broadcasting & communications equipment • New York
Armata Pharmaceuticals, Inc. Common Stock ($0.01 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • December 1st, 2025 • Armata Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Armata Pharmaceuticals, Inc., a Washington corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
AMENDMENT NO. 1 TO Capital on Demand™ SALES AGREEMENTCapital on Demand Sales Agreement • March 1st, 2019 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
TRACON Pharmaceuticals, Inc. (the “Company”), and JonesTrading Institutional Services LLC (“JonesTrading”), are parties to that certain Capital on DemandTM Sales Agreement dated September 6, 2018 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows (to be effective as set forth in paragraph 6 below):
PROSPECTUS SUPPLEMENTCapital on Demand Sales Agreement • April 30th, 2019 • Delaware
This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we have filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may offer any combination of our securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $180,000,000. The $50,000,000 of common stock that may be offered, issued and sold under this prospectus supplement is included in the $180,000,000 of securities that may be offered, issued and sold by us pursuant to our shelf registration statement.
SURFACE ONCOLGY, INC. Amendment No. 1 to Capital on DemandTM Sales AgreementCapital on Demand Sales Agreement • August 5th, 2021 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York